Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT07229313
Official study title

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Study summary

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedKIVU-107

The study team can explain what participation involves.

Who it may be forLocally advanced · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 24, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Kivu Bioscience Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Kivu Bioscience Inc.
Interventions being studied
Drug: KIVU-107
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Locally advanced→Metastatic or stage IV→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Male or female ≥18 years of age
  • No therapy of proven efficacy exists for the tumor
  • Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available.
  • Adequate bone marrow, kidney, and liver function
  • Measurable disease using RECIST v1.1
  • ECOG 0 or 1
  • Life expectancy ≥ 3 months
Reasons someone may not be able to joinExclusion criteria
  • Prior treatment with any ADC with topoisomerase 1 inhibitor payload
  • Any PTK7 - targeted therapy
  • Uncontrolled cardiovascular disease
  • Active Hepatitis B, Hepatitis C, or HIV infection
  • History of interstitial lung disease
  • Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Kivu Trial SiteSanta Monica, California
  • Kivu Trial SiteNew Have, Connecticut
  • Kivu Trial SiteCamperdown, New South Wales
  • Kivu Trial SiteSydney, New South Wales
  • Kivu Trial SiteBrisbane, Queensland
  • Kivu Trial SiteAdelaide, South Australia
  • Kivu Trial SiteGeelong, Victoria

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 24, 2026. Always confirm current availability with the study team.

View original record ↗